Loading...
Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
Ramalingam, S. S. Ahn, M. J. Akamatsu, H. Blackhall, Fiona H Borghaei, H. Hummel, H. D. Johnson, M. Reck, M. Zhang, Y. Jandial, D.
Ramalingam, S. S.
Ahn, M. J.
Akamatsu, H.
Blackhall, Fiona H
Borghaei, H.
Hummel, H. D.
Johnson, M.
Reck, M.
Zhang, Y.
Jandial, D.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Ramalingam SS, Ahn MJ, Akamatsu H, Blackhall F, Borghaei H, Hummel HD, et al. Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC). Annals of Oncology. 2022;33:S103-S4.